
Pediatrix Medical (MD) Stock
Major provider of hospital based neonatal and maternal care. Here's the price, business snapshot, and what's worth knowing about Pediatrix Medical in August 2026.
Pediatrix Medical Group, Inc. (MD) is a physician-led provider of neonatal, maternal–fetal, paediatric and other specialised hospital-based services, typically delivering care by staffing physicians, advanced practice clinicians and allied health professionals across hospitals and outpatient centres. With a market capitalisation around $1.47 billion, the company’s revenue model relies on contracts with hospitals and health systems, fee-for-service activity and payer reimbursements. Investors often watch utilisation trends (birth rates, hospital admissions), reimbursement policy and labour costs as primary profit drivers. Strengths can include stable demand for neonatal and maternal care and potential scale benefits from centralised clinical management; risks include regulatory and reimbursement changes, litigation exposure and variable hospital volumes. This summary is for general educational purposes only and is not personal financial advice — prospective investors should review the company’s filings, recent results and consult a financial adviser before deciding. Past performance is not a reliable indicator of future returns.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Pediatrix Medical Group's stock with a target price of $16.38, indicating strong growth potential.
Financial Health
Pediatrix Medical Group is showing solid revenue and cash flow, indicating strong operational performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Stable care demand
Neonatal and maternal services typically show steady demand, which can support revenue resilience, though hospital admission volumes can still fluctuate.
Operational leverage
Centralised staffing and clinical management may improve margins if utilisation rises, but benefits can be offset by labour and malpractice cost pressures.
Regulatory & payers
Reimbursement rules and payer mix (Medicaid/insurers) strongly influence profitability, so policy shifts or contract changes are important risks to monitor.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.